Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction

被引:29
作者
Trivedi, V. R. [1 ]
Satia, M. C. [1 ]
Deschamps, A. [2 ]
Maquet, V. [2 ]
Shah, R. B. [3 ]
Zinzuwadia, P. H. [4 ]
Trivedi, J. V. [5 ]
机构
[1] Titanium City Ctr, Ethicare Clin Trial Serv, Ahmadabad 380015, Gujarat, India
[2] KITOZYME, B-4040 Herstal, Belgium
[3] Poojan Multispecialty Hosp, Ahmadabad 380052, Gujarat, India
[4] DHL Res Ctr, Ahmadabad 380015, Gujarat, India
[5] SAL Hosp, Ahmadabad 380054, Gujarat, India
来源
NUTRITION JOURNAL | 2016年 / 15卷
关键词
Chitosan; Obesity; Randomised; Body weight; Anthropometric measurements; Body composition; HbA1C; ANTHROPOMETRIC MEASURES; OLIGOSACCHARIDE GO2KA1; CONTROLLED-TRIAL; HEALTH; CHOLESTEROL; OVERWEIGHT; PREVENTION; OBESITY; LIPIDS;
D O I
10.1186/s12937-016-0122-8
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Chitosan is a dietary fibre which acts by reducing fat absorption and thus used as a means for controlling weight. Weight loss clinical trial outcomes, however, have contradictory results regarding its efficacy. The primary objective of the present study was to evaluate the efficacy and safety of a chitosan from fungal origin in treatment of excess weight in the absence of dietary restrictions. Methods: A phase IV, randomised, multicentre, single-blind, placebo-controlled, clinical study was conducted by administering chitosan capsules (500 mg, five/day) and indistinguishable placebo capsules as daily supplements to 96 overweight and obese subjects for 90 days. The study participants were divided in 2: 1 ratio to receive either chitosan (n = 64) or placebo (n = 32). Efficacy was assessed by measuring body weight, body composition parameters, anthropometric measurements, HbA1C level and lipid profile at day 45 and day 90. Also, short form-36 quality of life (QoL) questionnaire was assessed to evaluate improvement in life-style and dietary habits were recorded for calorie intake. Safety was assessed by evaluating safety parameters and monitoring adverse events. Results: The mean changes in body weight were -1.78 +/- 1.37 kg and -3.10 +/- 1.95 kg at day 45 and day 90 respectively in chitosan group which were significantly different (p < 0.0001) as compared to placebo. BMI was decreased by10.91 fold compared to placebo after 90 day administration. In concert with this, there was also reduction in body composition and anthropometric parameters together with improvement in QoL score. Chitosan was also able to reduce HbA1C levels (below 6 %) in subjects who had initial higher values. The mean caloric intake shows that there was no change in dietary habits of subjects in both groups. Lipid levels were unaffected and all adverse events were mild in nature and unrelated to study treatment. Conclusion: Chitosan from fungal origin was able to reduce the mean body weight up to 3 kg during the 90 day study period. Together with this, there was also improvement in body composition, anthropometric parameters and HbA1C, reflecting overall benefits for the overweight individuals. Additionally, there was also improvement in QoL score. It was safe and well tolerated by all subjects.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults
    C Ni Mhurchu
    S D Poppitt
    A-T McGill
    F E Leahy
    D A Bennett
    R B Lin
    D Ormrod
    L Ward
    C Strik
    A Rodgers
    International Journal of Obesity, 2004, 28 : 1149 - 1156
  • [32] The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults
    Mhurchu, CN
    Poppitt, SD
    McGill, AT
    Leahy, FE
    Bennett, DA
    Lin, RB
    Ormrod, D
    Ward, L
    Strik, C
    Rodgers, A
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (09) : 1149 - 1156
  • [33] Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial
    Eckard, Allison Ross
    Wu, Qian
    Sattar, Abdus
    Ansari-Gilani, Kianoush
    Labbato, Danielle
    Foster, Theresa
    Fletcher, Aaron A.
    Adekunle, Ruth
    McComsey, Grace A.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08) : 523 - 534
  • [34] Changes in Body Weight and Knee Pain in Adults With Knee Osteoarthritis Three-and-a-Half Years After Completing Diet and Exercise Interventions: Follow-Up Study for a Single-Blind, Single-Center, Randomized Controlled Trial
    Messier, Stephen P.
    Newman, Jovita J.
    Scarlett, Matthew J.
    Mihalko, Shannon L.
    Miller, Gary D.
    Nicklas, Barbara J.
    DeVita, Paul
    Hunter, David J.
    Lyles, Mary F.
    Eckstein, Felix
    Guermazi, Ali
    Loeser, Richard F.
    Beavers, Daniel P.
    ARTHRITIS CARE & RESEARCH, 2022, 74 (04) : 607 - 616
  • [35] Clinical Efficacy of Potato Extract for Alleviating Chemoradiotherapy-Related Leukopenia: a Randomized, Single-Blind, Placebo-Controlled Trial
    Bao, Ying-Na
    Eerdemutu
    An, Zhi-Ling
    Zhang, Ji-Hong
    Niu, Li-Rong
    Yu, Zhi-Long
    Zhao, Jian-Guo
    CLINICAL LABORATORY, 2022, : 2186 - 2193
  • [36] The Role of High-Fat Ketogenic and Low-Fat Diets in Weight Reduction and Cardiovascular Risk Mitigation Among Overweight and Obese Women: A Single-Blind Controlled Study
    Alnoubi, Atheer Ahmad
    Alqurashi, Randah Miqbil
    CURRENT RESEARCH IN NUTRITION AND FOOD SCIENCE, 2024, 12 (03) : 1366 - 1375
  • [37] The effects of chitosan supplementation on body weight and body composition: a systematic review and meta-analysis of randomized controlled trials
    Huang, Haohai
    Liao, Dan
    Zou, Ying
    Chi, Honggang
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2020, 60 (11) : 1815 - 1825
  • [38] The effect of training on treatment adherence in coronary artery patients: A single-blind randomised controlled trial
    Dogan, Ugur
    Ovayolu, Nimet
    JOURNAL OF CLINICAL NURSING, 2022, 31 (5-6) : 744 - 754
  • [39] Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial
    Gudbergsen, Henrik
    Henriksen, Marius
    Waehrens, Eva Ejlersen
    Overgaard, Anders
    Bliddal, Henning
    Christensen, Robin
    Boesen, Mikael Ploug
    Knop, Filip Krag
    Astrup, Arne
    Rasmussen, Marianne Uggen
    Bartholdy, Cecilie
    Daugaard, Cecilie
    Bartels, Else Marie
    Ellegaard, Karen
    Heitmann, Berit Lilienthal
    Kristensen, Lars Erik
    BMJ OPEN, 2019, 9 (05):
  • [40] Normobaric Intermittent Hypoxia over 8 Months Does Not Reduce Body Weight and Metabolic Risk Factors - a Randomized, Single Blind, Placebo-Controlled Study in Normobaric Hypoxia and Normobaric Sham Hypoxia
    Gatterer, Hannes
    Haacke, Sven
    Burtscher, Martin
    Faulhaber, Martin
    Melmer, Andreas
    Ebenbichler, Christoph
    Strohl, Kingman P.
    Hoegel, Josef
    Netzer, Nikolaus C.
    OBESITY FACTS, 2015, 8 (03) : 200 - 209